FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2771011851> ?p ?o ?g. }

• W2771011851 endingPage "1101" @default.
• W2771011851 startingPage "1083" @default.
• W2771011851 abstract "Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic dermatitis, and side-effects limit its use. Dupilumab, a fully human anti-interleukin 4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of Type 2/Th2-mediated inflammation, and is approved in the U.S.A. and the European Union for the treatment of inadequately-controlled moderate-to-severe atopic dermatitis in adults.To evaluate efficacy and safety of dupilumab with concomitant topical corticosteroids (TCS) in adults with atopic dermatitis with inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable.In this 16-week, double-blind, randomized, placebo-controlled, phase III trial, patients were randomized 1 : 1 : 1 to subcutaneous dupilumab 300 mg weekly (qw) or every 2 weeks (q2w) or placebo. All received concomitant medium-potency TCS from Week -2 through Week 16; dosage could be tapered if lesions cleared, or stopped for adverse reactions to TCS.In total, 390 patients were screened, 325 were randomized, and 318 completed the trial. Treatment groups had similar baseline characteristics. Significantly more patients in the dupilumab qw + TCS and q2w + TCS groups achieved ≥ 75% improvement from baseline in the Eczema Area and Severity Index at Week 16 vs. the placebo + TCS group (primary end point) (59·1% and 62·6% vs. 29·6%, respectively; P < 0·001 vs. placebo + TCS, both doses). Other clinical outcomes and atopic dermatitis symptoms were significantly improved in the dupilumab qw + TCS and q2w + TCS groups, including pruritus, pain, sleep disturbance, symptoms of anxiety and depression, and quality of life (QoL). Treatment groups had similar overall rates of adverse events (qw + TCS, q2w + TCS and placebo + TCS groups: 69·1%, 72·0% and 69·4%, respectively) and serious adverse events (1·8%, 1·9% and 1·9%, respectively). Conjunctivitis was more frequent with dupilumab + TCS; skin infections were more frequent with placebo + TCS.Dupilumab + TCS significantly improved signs and symptoms of atopic dermatitis and QoL in adults with a history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified." @default.
• W2771011851 created "2017-12-04" @default.
• W2771011851 creator A5000572878 @default.
• W2771011851 creator A5005306967 @default.
• W2771011851 creator A5022486443 @default.
• W2771011851 creator A5026963044 @default.
• W2771011851 creator A5052196009 @default.
• W2771011851 creator A5054320048 @default.
• W2771011851 creator A5060607282 @default.
• W2771011851 creator A5069935041 @default.
• W2771011851 creator A5071078845 @default.
• W2771011851 creator A5075904620 @default.
• W2771011851 creator A5077097587 @default.
• W2771011851 creator A5077395512 @default.
• W2771011851 creator A5085831636 @default.
• W2771011851 creator A5087031898 @default.
• W2771011851 creator A5088410595 @default.
• W2771011851 date "2018-03-25" @default.
• W2771011851 modified "2023-10-15" @default.
• W2771011851 title "Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t" @default.
• W2771011851 cites W1583257755 @default.
• W2771011851 cites W1858234123 @default.
• W2771011851 cites W189068515 @default.
• W2771011851 cites W1969725546 @default.
• W2771011851 cites W1980040943 @default.
• W2771011851 cites W1987138256 @default.
• W2771011851 cites W1994262603 @default.
• W2771011851 cites W2002600662 @default.
• W2771011851 cites W2029208193 @default.
• W2771011851 cites W2032676695 @default.
• W2771011851 cites W2038602102 @default.
• W2771011851 cites W2058562555 @default.
• W2771011851 cites W2058945293 @default.
• W2771011851 cites W2063478454 @default.
• W2771011851 cites W2064583078 @default.
• W2771011851 cites W2067545345 @default.
• W2771011851 cites W2068370036 @default.
• W2771011851 cites W2076922731 @default.
• W2771011851 cites W2093668721 @default.
• W2771011851 cites W2098889816 @default.
• W2771011851 cites W2116889630 @default.
• W2771011851 cites W2117983771 @default.
• W2771011851 cites W2118630839 @default.
• W2771011851 cites W2120110016 @default.
• W2771011851 cites W2122022191 @default.
• W2771011851 cites W2122674341 @default.
• W2771011851 cites W2139696655 @default.
• W2771011851 cites W2142327072 @default.
• W2771011851 cites W2167829087 @default.
• W2771011851 cites W2174132185 @default.
• W2771011851 cites W2200308911 @default.
• W2771011851 cites W2266684950 @default.
• W2771011851 cites W2276335262 @default.
• W2771011851 cites W2306524933 @default.
• W2771011851 cites W2316573767 @default.
• W2771011851 cites W2342693354 @default.
• W2771011851 cites W2346847441 @default.
• W2771011851 cites W2358033148 @default.
• W2771011851 cites W2419580390 @default.
• W2771011851 cites W2524051065 @default.
• W2771011851 cites W2566687596 @default.
• W2771011851 cites W2586378708 @default.
• W2771011851 cites W2590317180 @default.
• W2771011851 cites W2610814011 @default.
• W2771011851 cites W2613379575 @default.
• W2771011851 cites W2731948244 @default.
• W2771011851 cites W2734328927 @default.
• W2771011851 cites W2736191657 @default.
• W2771011851 cites W2744776760 @default.
• W2771011851 cites W2755633626 @default.
• W2771011851 cites W3214321974 @default.
• W2771011851 cites W4211044813 @default.
• W2771011851 cites W4366807517 @default.
• W2771011851 cites W2589472507 @default.
• W2771011851 doi "https://doi.org/10.1111/bjd.16156" @default.
• W2771011851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29193016" @default.
• W2771011851 hasPublicationYear "2018" @default.
• W2771011851 type Work @default.
• W2771011851 sameAs 2771011851 @default.
• W2771011851 citedByCount "326" @default.
• W2771011851 countsByYear W27710118512018 @default.
• W2771011851 countsByYear W27710118512019 @default.
• W2771011851 countsByYear W27710118512020 @default.
• W2771011851 countsByYear W27710118512021 @default.
• W2771011851 countsByYear W27710118512022 @default.
• W2771011851 countsByYear W27710118512023 @default.
• W2771011851 crossrefType "journal-article" @default.
• W2771011851 hasAuthorship W2771011851A5000572878 @default.
• W2771011851 hasAuthorship W2771011851A5005306967 @default.
• W2771011851 hasAuthorship W2771011851A5022486443 @default.
• W2771011851 hasAuthorship W2771011851A5026963044 @default.
• W2771011851 hasAuthorship W2771011851A5052196009 @default.
• W2771011851 hasAuthorship W2771011851A5054320048 @default.
• W2771011851 hasAuthorship W2771011851A5060607282 @default.
• W2771011851 hasAuthorship W2771011851A5069935041 @default.
• W2771011851 hasAuthorship W2771011851A5071078845 @default.
• W2771011851 hasAuthorship W2771011851A5075904620 @default.
• W2771011851 hasAuthorship W2771011851A5077097587 @default.

• next